Chemotherapy Induced Neutropenia (CIN) Market Research Report 2023

1. Chemotherapy Induced Neutropenia (CIN) Market Insights and Market Forecast Report 2023 Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology and Market Forecast-2023” to its report offerings.The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts. Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1045347 DelveInsight’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted data of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 Cancer indications till 2023. The report covers the number of patients for 10 cancer indications (i.e. Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin’s disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers. Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved

2. in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the Global Market size of CIN in 2016 was USD 3.67 Billion. Table of Content: Report Introduction Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance Global Market Size of CIN in 2016 Global Market Size of CIN in 2023 Chemotherapy Induced Neutropenia (CIN) Overview Causes of Neutropenia Common cycle of chemotherapy-related neutropenia Signs and symptoms Risk Factors Severity and Grades of Neutropenia Pathophysiology/ Mechanisms of action Diagnosis Epidemiology and Patient Population Assumptions and Caveats United States Incident Cases of ten major Cancer indications in United States Read Full Report with TOC: http://www.marketresearchhub.com/report/chemotherapy-induced-neutropenia- cin-market-insights-epidemiology-and-market-forecast2023-report.html Buy Report Now!

3. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Details: 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Website: http://www.marketresearchhub.com/ Follow Us on: Twitter, LinkedIn, Facebook